Skip to main content
U.S. flag

An official website of the United States government

Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease


Year of Publication:
Contact PI Name:
Roberta Diaz Brinton
Contact PI Affiliation:
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA
Liqin Zhao, Zisu Mao, Shuhua Chen, Lon S. Schneider
Primary Reference (PubMED ID):
Funding Source:
National Institute on Aging (NIA)
Alzheimer's Association
Bensussen Translational Research Fund
Study Goal and Principal Findings:

The goal of this study was to investigate the efficacy, in young female 3x Tg-AD mice, of a phyto- β-SERM formulation in the regulation of early stages of physical and neurological changes associated with AD. Results demonstrated that when initiated prior to the appearance of any signs of AD-related behavior or neuropathology, a 9-month dietary supplementation with the phyto-β-SERM formulation, at a dose biologically equivalent to a daily intake of 50mg in humans, promoted physical health, prolonged survival, improved spatial recognition memory, and attenuated eventual amyloid-beta deposition and plaque formation in treated AD mice. In comparison, dietary supplementation of a commercial soy extract preparation showed no effect on cognitive measures, although it appeared to have a positive impact on beta amyloid pathology. These findings, along with those found in a preclinical model of human menopause , have recently led to a clinical trial of the phyto-β-SERM formulation designed to evaluate the dosage/safety, pharmacokinetics, and proof-of-concept efficacy to mitigate hot flash frequency and memory deficits in menopausal women ( identifier: NCT01723917).

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Natural Product
Therapeutic Agent:
Phyto-β-SERM Formulation
Therapeutic Target:
Estrogen Receptor

Animal Model

Model Information:
Model Type:
Strain/Genetic Background:
Not Reported

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest


Outcome Measured
Outcome Parameters
Y Maze
Prolonged Survival
beta Amyloid Deposits
Brain-beta Amyloid Peptide 40
Brain-beta Amyloid Peptide 42
Gene Expression Profile
Body Weight